Back to Network
3
Shared Docs
3
Same-Page
3 / 3
Mentions
Document Mentions (3 shared documents)
2 mentions1 same-page
Page ?Same page
uction with Evolocumab Reply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2
ply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2017 American College of Cardiology Scientific Session in Was
2 mentions1 same-page
Page ?Same page
cumab Reply-To: Cardiology Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2
y Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was
2 mentions1 same-page
Page ?Same page
eduction with Evolocumab Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2
Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was
Sponsored
Mutual Connections (15)
Entities connected to both Evolocumab and the Further Cardiovascular Outcomes Research
American Medical Communications
ORGANIZATION3 w/ Evolocumab·3 w/ the
Lesley Groff
PERSON3 w/ Evolocumab·3 w/ the
Harvard Medical School
ORGANIZATION3 w/ Evolocumab·3 w/ the
Manalapan
LOCATION3 w/ Evolocumab·3 w/ the
Mount Sinai
ORGANIZATION3 w/ Evolocumab·3 w/ the
Keech AC
ORGANIZATION3 w/ Evolocumab·3 w/ the
Jeffrey Epstein
PERSON3 w/ Evolocumab·3 w/ the
RS
Rony Shimony
PERSON3 w/ Evolocumab·3 w/ the
Icahn School of Medicine at Mount Sinai
ORGANIZATION3 w/ Evolocumab·3 w/ the
MS
Marc S. Sabatine
PERSON3 w/ Evolocumab·3 w/ the
SA
Sabatine
PERSON3 w/ Evolocumab·3 w/ the
GR
Giugliano RP
PERSON3 w/ Evolocumab·3 w/ the
American College of Cardiology 2017 Scientific Session
ORGANIZATION3 w/ Evolocumab·3 w/ the
Brigham and Women's Hospital
ORGANIZATION2 w/ Evolocumab·2 w/ the
Sabatine M. Primary
ORGANIZATION2 w/ Evolocumab·2 w/ the